APVO - Aptevo Therapeutics Inc Stock Price, Fair Value and News

$4.41-0.12 (-2.65%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

APVO Price Action

Last 7 days

6.6%

Last 30 days

-59.4%

Last 90 days

-30.7%

Trailing 12 Months

-98.6%

APVO RSI Chart

APVO Valuation

Market Cap

2.2M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

0.71

EV/EBITDA

0.08

Price/Free Cashflow

-0.09

APVO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

APVO Fundamentals

APVO Revenue

Revenue (TTM)

3.1M

APVO Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

19.47%

Earnings Growth (Qtr)

13.29%

APVO Profitability

EBT Margin

-1666.57%

Return on Equity

-536.66%

Return on Assets

-156.61%

Free Cashflow Yield

-1.1K%

APVO Investor Care

Shares Dilution (1Y)

4523.61%

Diluted EPS (TTM)

-632.88

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	13.0M	37.7M	20.4M	3.1M
2021	6.8M	9.4M	11.0M	12.3M
2020	0	23.1M	13.7M	4.3M
2019	26.0M	26.6M	29.7M	32.4M
2018	16.6M	19.9M	19.5M	23.1M
2017	23.9M	17.3M	20.6M	14.7M
2016	30.0M	33.1M	29.4M	29.8M
2015	0	0	0	33.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

CEO	Mr. Marvin L. White
WEBSITE	aptevotherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	45

Aptevo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aptevo Therapeutics Inc? What does APVO stand for in stocks?

APVO is the stock ticker symbol of Aptevo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptevo Therapeutics Inc (APVO)?

As of Fri Dec 20 2024, market cap of Aptevo Therapeutics Inc is 2.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers.

Is Aptevo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APVO is over valued or under valued. Whether Aptevo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aptevo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APVO.

What is Aptevo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, APVO's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 0.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APVO PE ratio will change depending on the future growth rate expectations of investors.